TISSUE MODELING CORE

项目摘要：组织建模核心 组织建模核心(TMC)的长期目标是提供不断增长的固定和活体档案 用于测序的组织、DNA和RNA将支持佛罗里达-加利福尼亚州卫生公平中心的 任务。TMC将开发一个强大的、注释良好的组织样本生物存储库，这些样本来自种族和 佛罗里达州和加利福尼亚州不同种族的患者群体，并将他们提供给Care2中心 调查人员。TMC的短期目标是为这三个项目提供必要的组织样本 同时为现有和即将到来的Care2项目的未来需求做准备。TMC将解决 在医学研究中招募黑人和拉丁裔面临的挑战和高质量生物谱系的有限供应 以及这些种群的基因组数据。TMC的具体目标是： 目标1.开发一个虚拟存储库，它将提供对不同肿瘤的生物标本的访问 通过Care2中心提供的单一接入点访问存储库。许多癌症类型一直是 与结果差异有关，差异的原因包括遗传、获得护理的机会、共病、 和生活方式。目标1A：组织和生物材料收集。建立的组织模型库将 包括：(1)UF CTSI组织储存库；和(2)链接到 加州癌症登记处和诺里斯综合癌症中心/洛杉矶县医疗中心 病人样本。TMC的近期任务包括：(1)全面项目1：提供组织、血浆、血清、 和评估前列腺癌线粒体多肽和转录组学所需的RNA；(2)完整 项目2：提供胰腺癌组织和RNA以了解吉西他滨对胰腺的疗效 癌症；和(3)试点项目3：提供正常胰腺组织和用于理解的测序 胰腺癌的发展。目标1B：将基础设施移交给金融资产管理股。TMC还将寻求扩张 固定和活组织的FAMU基础设施。它将利用合作的CTSI来利用这种增长， 癌症中心和One佛罗里达临床研究联盟。 目的2.活体组织和活体肿瘤组织的获取。管委会的当前任务包括： (1)完整项目2：提供胰腺癌PDX和成对细胞系，用于二维和三维建模；及 试点项目3：为接受胰腺手术的患者提供正常的活胰腺组织 良性疾病。 通过实现这些具体目标，TMC将：(1)加强癌症差异科学在重要的 组织建模研究领域；(2)通过以下方式有效地扩展Care2研究人员的癌症差异资源 利用佛罗里达州和加利福尼亚州的专业知识、服务和设施，以及(3)确保持续关注 转让技术诀窍、技术和与FAMU的协作。

PROJECT ABSTRACT: TISSUE MODELING CORE The long-term goal of the Tissue Modeling Core (TMC) is to provide a growing archive of fixed and living tissues, DNA, and RNA for sequencing that will support the Florida-California CaRE2 Health Equity Center’s mission. The TMC will develop a robust, well-annotated biorepository of tissue samples from a racially and ethnically diverse Florida and California patient population and make them available to the CaRE2 Center investigators. The short-term goals of the TMC are to provide the necessary tissue samples for the three projects while preparing for the future needs of the existing and upcoming CaRE2 projects. The TMC will address the challenge of recruiting Blacks and Latinos in medical research and the limited supply of quality biospecimens and genomic data for these populations. The TMC Specific Aims are to: Aim 1. Develop a virtual repository that will provide access to biospecimens from diverse tumor repositories through a single access point provided by the CaRE2 Center. Many cancer types have been linked to outcome disparities, with the causes of disparities including genetics, access to care, comorbidities, and lifestyle. Aim 1A: Tissue and biomaterials collection. The established tissue-modeling repository will comprise: (1) the UF CTSI tissue repositories; and (2) the USC Residual Tissue Repository linked to the California Cancer Registry and Norris Comprehensive Cancer Center/Los Angeles County Medical Center patient samples. The immediate tasks of the TMC include: (1) Full Project 1: provision of tissue, plasma, serum, and RNA needed for evaluation of mitochondrial peptidomics and transcriptomics of prostate cancer; (2) Full Project 2: provision of tissue and RNA of pancreatic cancers to understand gemcitabine efficacy in pancreatic cancer; and (3) Pilot Project 3: provision of normal pancreas tissues and sequencing for understanding pancreatic cancer development. Aim 1B: Infrastructure transfer to FAMU. The TMC will also seek to expand the FAMU infrastructure for fixed and living tissues. It will leverage that growth using the cooperating CTSIs, Cancer Centers, and the OneFlorida Clinical Research Consortium. Aim 2. Living tissue and living tumor tissue acquisition. The immediate tasks of the TMC include: (1) Full Project 2: provision of pancreatic cancer PDXs and paired cell lines for 2D and 3D modeling; and (2) Pilot Project 3: provision of normal living pancreas tissues from patients undergoing pancreatic surgery for benign disease. By achieving these Specific Aims, the TMC will: (1) enhance cancer disparities science in the important areas of tissue-modeling research; (2) efficiently expand cancer disparities resources for CaRE2 researchers by leveraging the expertise, services, and facilities in Florida and California, and (3) ensure a sustained focus on transferring know-how, technology, and collaborations with FAMU.